



115th MAINE LEGISLATURE

SECOND SPECIAL SESSION-1992

Legislative Document

No. 2420

H.P. 1729

House of Representatives, March 12, 1992

Approved for introduction by a majority of the Legislative Council pursuant to Joint Rule 27. Reference to the Committee on Judiciary suggested and ordered printed.

EDWIN H. PERT, Clerk

Presented by Representative POWERS of Coplin Plantation. Cosponsored by Representative LARRIVEE of Gorham, Senator CONLEY of Cumberland and Representative ALIBERTI of Lewiston.

STATE OF MAINE

IN THE YEAR OF OUR LORD NINETEEN HUNDRED AND NINETY-TWO

An Act to Legalize Marijuana for Medicinal Purposes.

(AFTER DEADLINE)

Printed on recycled paper

	Be it enacted by the People of the State of Maine as follows:						
2	Sec.1. 5 MRSA § 12004-G, sub-§14-B is enacted to read:						
4							
	14-B. Participation <u>\$40/Day</u> <u>22 MRSA</u>						
6	Human Review Board §2425						
	<u>Services</u>						
8							
	Sec. 2. 22 MRSA c. 558-C is enacted to read:						
10	CHAPTER 558-C						
12							
	MARIJUANA THERAPEUTIC RESEARCH PROGRAM						
14							
	§2421. Short title						
16	This shorter may be sited as the "Maringana Therapoutis						
10	This chapter may be cited as the "Marijuana Therapeutic Research Act "						
18	Research Act."						
20	§2422. Findings and purpose						
	in an ann an Anna an Anna ann an Anna a Anna an Anna an						
2.2	The Legislature finds that research has recently indicated						
	that the use of marijuana may alleviate nausea and certain other						
24	side effects of cancer chemotherapy as well as some symptoms of						
	glaucoma. The Legislature also finds that further research and						
26	strictly controlled experimentation regarding the therapeutic						
	uses of marijuana are necessary and desirable. The purpose of						
28	this chapter is to facilitate and encourage this research and						
_	experimentation.						
30	n an						
	§2423. Definitions						
32							
	As used in this chapter, unless the context indicates						
34	otherwise, the following terms have the following meanings.						
n c							
36	1. Board. "Board" means the Board of Registration in						
	Medicine as established in Title 5, $12004-A$, subsection 24.						
38 ·							
	2. Marijuana. "Marijuana" means marijuana.						
10	<u>tetrahydrocannabinol or a chemical derivative of</u>						
	<u>tetrahydrocannabinol.</u>						
12							
	3. Practitioner. "Practitioner" means an allopathic or						
14	osteopathic physician licensed to practice in this State.						
46	4. Program. "Program" means the Marijuana Therapeutic						
- 0	Research Program.						
48	-						
	<u> S2424. Marijuana Therapeutic Research Program</u>						
50	Jarger moteljumu merupeutet keptulen rivytum						

Page 1-LR2959(1) L.D.2420

and the second

1. Establishment; administration. There is established within the department the Marijuana Therapeutic Research Program, administered by the commissioner.

2. Rules. Subject to Title 5, chapter 375, the department
 shall adopt rules necessary for the proper administration of the program. In adopting rules, the department shall consider
 8 pertinent rules adopted by the federal Drug Enforcement Agency, the federal Food and Drug Administration, the National Institute
 10 on Drug Abuse and any another federal agency concerned with the subject of this chapter.

3. Supply. The commissioner shall contract with the 14National Institute on Drug Abuse for the receipt of marijuana under rules adopted by the National Institute on Drug Abuse, the federal Food and Drug Administration and the federal Drug 16 Enforcement Agency. If, within a reasonable period of time, the commissioner is unable to obtain marijuana as provided in this 18 subsection, the commissioner shall contract with appropriate law enforcement agencies in this State for the receipt of confiscated 20 marijuana not intended for use as evidence in any criminal 22 proceeding. Any marijuana so received must be made free of impurities and analyzed for potency by the department. 24

4. Distribution. The commissioner shall deliver marijuana
 received under subsection 3 to appropriate state or privately operated licensed pharmacies designated by the commissioner. Any
 marijuana so delivered must be distributed to patients upon the written prescription of their approved practitioners. Any
 privately operated licensed pharmacy designated by the commissioner under this subsection is not liable, except for
 gross negligence, in any civil action on account of marijuana distributed to patients under this chapter.

36 §2425. Participation in the program

2

4

12

34

 38 <u>1. Application. Any practitioner who wants to participate in the program must apply to the board for approval and pay a \$50
 40 application fee.
</u>

 42 2. Review and approval. The board shall review all applicants and, if they are eligible under subsection 3 and the
 44 rules adopted by the department under section 2424, subsection 2, shall approve them for participation. In performing these
 46 duties, the board is subject to Title 5, chapter 375.

48	3. Presci	iptions.	A p	ractition	ler approved	for
	<u>participation in</u>	the progr	<u>am may</u>	prescribe	<u>e marijuana t</u>	<u>o only</u>
50	those patients	who are	undergoi	ng canc	er chemothera	ipy or
	suffering from	glaucoma,	are	in a	life-threateni	ng or
52	sense-threatening	situation	and w	who are	<u>not respondi</u>	ng to

Page 2-LR2959(1) L.D.2420 conventional treatment or who are suffering severe side effects even though conventional treatment is proving effective.

4 §2426. Expressly authorized possession, prescription and distribution

A practitioner approved for participation in the program is 8 expressly authorized to prescribe marijuana under this chapter. A patient for whom marijuana has been prescribed by a 10 practitioner approved for participation in the program is expressly authorized to possess marijuana under this chapter. A 12 state or privately operated licensed pharmacy designated by the commissioner is expressly authorized to possess and distribute 14 marijuana under this chapter.

16 §2427. Confidentiality

 18 <u>1. Access to information.</u> Only the following persons have access to the name and other identifying characteristics of a
 20 patient for whom marijuana has been prescribed under this chapter:

22 A. The commissioner;

24 <u>B. The board;</u>

26 <u>C. The Attorney General or the Attorney General's designee;</u>

28 D. Any person directly connected with the program who has a legitimate need for the information; and

- E. Any person for whom access has been specifically 32 authorized by that patient.
- 34 <u>Meetings and records of the board are not subject to the</u> requirements of Title 1, chapter 13.

2. Exceptions. Nothing in this section may affect the right to inspect the records of any pharmacy under Title 32, section 13723, or prohibit access to or release of information concerning any persons acting under authority of this chapter with respect to conduct not expressly authorized by this chapter.

<u>§2428. Reports</u>

44

48

50

42

30

36

2

6

The commissioner and the board shall report annually their findings and recommendations regarding the program to the <u>Governor and the Legislature.</u>

STATEMENT OF FACT

52

Page 3-LR2959(1) L.D.2420

This bill reestablishes the Marijuana Therapeutic Research 2 Program administered by the Commissioner of Human Services, which was repealed December 31, 1987. The Board of Registration in Medicine must review any patient wishing to participate in the 4 program. Participation is limited to cancer chemotherapy and 6 glaucoma patients who are not responding to conventional treatment or who are suffering severe side effects, and any other patient where medical evidence presented to the board justifies 8 that participation. If the board approves a patient, the patient's physician may write a prescription that can be filled 10 at a state or privately operated licensed pharmacy designated by 12 the board. The commissioner may obtain analyzed marijuana available from the Federal Government and deliver it to the pharmacy for dispensing to any approved patient with a written 14 prescription from the patient's physician. The commissioner and 16 the board are required to make an annual report to the Governor and the Legislature, enabling both the legislative branch and 18 executive branch to monitor the program closely.